2024
Using Data-To-Care Strategies to Optimize the HIV Care Continuum in Connecticut: Results From a Randomized Controlled Trial
Machavariani E, Miceli J, Altice F, Fanfair R, Speers S, Nichols L, Jenkins H, Villanueva M. Using Data-To-Care Strategies to Optimize the HIV Care Continuum in Connecticut: Results From a Randomized Controlled Trial. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2024, 96: 40-50. PMID: 38324241, DOI: 10.1097/qai.0000000000003391.Peer-Reviewed Original ResearchDisease intervention specialistsCare continuum outcomesHIV care continuum outcomesHIV care continuumRandomized controlled trialsHIV risk categoryCare continuumStandard-of-careData-to-CareViral suppressionRe-engagementPredictor of re-engagementRisk categoriesHIV careRe-engage peopleMultivariate regression modelHIV clinicPredictors of retentionDetectable HIV-1 RNAIntervention specialistsControlled trialsPre-randomizationPredictors of VSCareHIV-1 RNA
2023
Using the exploration, preparation, implementation, sustainment (EPIS) framework to assess the cooperative re-engagement controlled trial (CoRECT)
Elder H, Lang S, Villanueva M, John B, Roosevelt K, Altice F, Brady K, Gibson B, Buchelli M, DeMaria A, Randall L. Using the exploration, preparation, implementation, sustainment (EPIS) framework to assess the cooperative re-engagement controlled trial (CoRECT). Frontiers In Public Health 2023, 11: 1223149. PMID: 38106893, PMCID: PMC10722986, DOI: 10.3389/fpubh.2023.1223149.Peer-Reviewed Original ResearchConceptsPublic health surveillance dataHealth surveillance dataHIV careSurveillance dataHealth department jurisdictionsPublic health practicePublic health agenciesStudy protocolClinic dataClinic partnersCase identificationHealth practicesHealth agenciesIntervention design processTrial sitesIntervention developmentTrialsCareInterventionSustainment (EPIS) frameworkEPIS frameworkIterative discussionsStaff capacityCommunity partnersRe-EngagementImproving HIV and HCV Testing in Substance Use Disorder Programs (SUDs) That Provide Medications for Opiate Use Disorder (MOUD): Role of Addressing Barriers and Implementing Universal and Site-Specific Approaches
Brooks R, Wegener M, Freeman B, Fowles C, Madden L, Tetrault J, Nichols L, Altice F, Villanueva M. Improving HIV and HCV Testing in Substance Use Disorder Programs (SUDs) That Provide Medications for Opiate Use Disorder (MOUD): Role of Addressing Barriers and Implementing Universal and Site-Specific Approaches. Health Promotion Practice 2023, 24: 1018-1028. PMID: 37439759, DOI: 10.1177/15248399231169791.Peer-Reviewed Original ResearchConceptsHIV/HCV coinfectionSubstance use disorder programsHCV testingOpiate use disorderHCV coinfectionUse disordersNominal group techniqueSubstance use disorder treatment centersCascade of careRates of HIVDisorder treatment centersQuality improvement effortsRate of testingHCV acquisitionHCV cureImproving HIVSUD clinicsHepatitis CHIV testingPrior diagnosisSubsequent referralReferral ratesHIV epidemicHIVTreatment centersChallenges to Achieving HCV Micro-Elimination in People With HIV in the United States: Provider Perspectives and the Role of Implicit Bias
DiDomizio E, Chandra D, Nichols L, Villanueva M, Altice F. Challenges to Achieving HCV Micro-Elimination in People With HIV in the United States: Provider Perspectives and the Role of Implicit Bias. Health Promotion Practice 2023, 24: 998-1008. PMID: 37440258, DOI: 10.1177/15248399231169928.Peer-Reviewed Original ResearchConceptsNominal group techniqueHealth care decisionsProvider perspectivesEligibility criteriaHIV/HCVEffective antiviral medicationsPatient eligibility criteriaFacilitators of treatmentMicro-EliminationHCV treatmentAntiviral medicationsOpioid epidemicProvider knowledgePatient involvementPatient engagementDifferent clinicsRelated stigmaHCVCare decisionsHIVPatientsTreatmentGroup sessionsMost barriersFocus group sessionsThe Cooperative Re-Engagement Controlled Trial (CoRECT): Durable Viral Suppression Assessment
O'Shea J, Fanfair R, Williams T, Khalil G, Brady K, DeMaria A, Villanueva M, Randall L, Jenkins H, Altice F, Camp N, Lucas C, Buchelli M, Samandari T, Weidle P. The Cooperative Re-Engagement Controlled Trial (CoRECT): Durable Viral Suppression Assessment. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2023, 93: 134-142. PMID: 36812382, PMCID: PMC10962216, DOI: 10.1097/qai.0000000000003178.Peer-Reviewed Original ResearchConceptsDurable viral suppressionActive public health interventionProportion of PWHPublic health interventionsViral loadCare strategiesHealth interventionsLast viral loadCopies/mLStandard of careRace/ethnicityCare armHIV careViral suppressionAntiretroviral adherenceCD4 categoryExposure categoriesCare individualsPWHCareAge categoriesInterventionTrialsBirth sexRe-EngagementCosts and cost‐effectiveness of a collaborative data‐to‐care intervention for HIV treatment and care in the United States
Shrestha R, Fanfair R, Randall L, Lucas C, Nichols L, Camp N, Brady K, Jenkins H, Altice F, DeMaria A, Villanueva M, Weidle P. Costs and cost‐effectiveness of a collaborative data‐to‐care intervention for HIV treatment and care in the United States. Journal Of The International AIDS Society 2023, 26: e26040. PMID: 36682053, PMCID: PMC9867888, DOI: 10.1002/jia2.26040.Peer-Reviewed Original ResearchConceptsCare armHIV careCare patientsIntervention armCare interventionsHealth departmentsHIV care interventionsHIV care outcomesHIV care providersHealthcare provider perspectiveHIV clinicHIV treatmentCare providersControl trialCare outcomesMicrocosting approachCare programCare servicesSurveillance dataSimilar interventionsIncremental costIntervention costsProvider perspectivesCareAverage cost
2022
Advancing data to care strategies for persons with HIV using an innovative reconciliation process
Villanueva M, Miceli J, Speers S, Nichols L, Carroll C, Jenkins H, Altice F. Advancing data to care strategies for persons with HIV using an innovative reconciliation process. PLOS ONE 2022, 17: e0267903. PMID: 35511958, PMCID: PMC9071117, DOI: 10.1371/journal.pone.0267903.Peer-Reviewed Original ResearchConceptsDisease intervention specialistsHIV care continuumCare continuumNon-randomized patientsPublic health surveillance dataOngoing HIV transmissionClinic visit dataHealth surveillance dataPublic health surveillanceHIV clinicHIV eliminationViral loadHIV transmissionCare engagementCopies/Clinic staffClinic dataYale University SchoolVisit dataHealth surveillancePWHSurveillance dataPatientsCells/Intervention specialists
2021
Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients
Sivakumar A, Madden L, DiDomizio E, Eller A, Villanueva M, Altice FL. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients. International Journal Of Drug Policy 2021, 101: 103570. PMID: 34954493, PMCID: PMC8685180, DOI: 10.1016/j.drugpo.2021.103570.Peer-Reviewed Original ResearchConceptsOpioid use disorderHepatitis C virusSyringe services programDifferentiated care modelPerson visitsC virusCare modelUse disordersInitiation of DAAChronic HCV infectionEvidence-based treatmentsCOVID-19Initial phlebotomyVirological responseHCV infectionHCV treatmentAdditional patientsElevated riskPatientsClient-centred approachPWIDHIVPerson contactTreatment demandLaboratory screeningThe Cooperative Re-Engagement Controlled trial (CoRECT): A randomised trial to assess a collaborative data to care model to improve HIV care continuum outcomes
Fanfair R, Khalil G, Williams T, Brady K, DeMaria A, Villanueva M, Randall L, Jenkins H, Altice F, Camp N, Lucas C, Buchelli M, Samandari T, Weidle P. The Cooperative Re-Engagement Controlled trial (CoRECT): A randomised trial to assess a collaborative data to care model to improve HIV care continuum outcomes. The Lancet Regional Health - Americas 2021, 3: 100057. PMID: 36777404, PMCID: PMC9903939, DOI: 10.1016/j.lana.2021.100057.Peer-Reviewed Original ResearchActive public health interventionMonths of randomizationViral load suppressionHIV viral loadPublic health interventionsViral loadCD4 countViral suppressionCare participantsCare strategiesHealth departmentsHealth interventionsDays of randomizationProportion of PWHStandard of careNon-Hispanic blacksHIV careContinuum outcomesHIV infectionMedian timeHIV transmissionCopies/Group overallClinic dataMedical care
2020
Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes
Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes. CHEST Journal 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.Peer-Reviewed Original ResearchConceptsCytokine release syndromeTocilizumab-treated patientsSevere diseaseRelease syndromeTocilizumab treatmentInflammatory biomarkersNonsevere diseaseSoluble IL-2 receptor levelsHigh-sensitivity C-reactive proteinIL-2 receptor levelsConsecutive COVID-19 patientsIL-6 receptor antagonistMechanical ventilation outcomesC-reactive proteinCOVID-19 patientsHigher admission levelsRace/ethnicityMV daysVentilation outcomesAdverse eventsChart reviewClinical responseMedian ageWhite patientsClinical outcomes
2019
Implementing Data to Care-What Are the Costs for the Health Department?
Neblett Fanfair R, Shrestha RK, Randall L, Lucas C, Nichols L, Camp NM, Brady K, Jenkins H, Altice F, Villanueva M, DeMaria A. Implementing Data to Care-What Are the Costs for the Health Department? JAIDS Journal Of Acquired Immune Deficiency Syndromes 2019, 82 Suppl 1: s57-s61. PMID: 31425397, DOI: 10.1097/qai.0000000000001968.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply